Diabetes, a leading cause of death in developed countries, is a metabolic disease characterized by the loss of glucose homeostasis due to defective insulin function. There are two main types of diabetes depending on whether the defect results from insufficient insulin production by the pancreatic β cells (type 1) or is due to insensitivity of peripheral tissues (such as skeletal muscle, liver, or adipose tissue) to secreted insulin (type 2). The decreased insulin sensitivity of peripheral tissues in type 2 diabetes, which accounts for ?90% of all cases of the disease, is initially compensated for by increased secretion of insulin by the β cells of the pancreas. However, as the disease progresses, elevated insulin secretion leads to β cell damage and eventual loss of insulin production. In this issue of Cell, Sumara et al. (2009) define a new regulatory module involving the p38 mitogen-activated protein kinase (MAPK) family member p38δ (also referred to as SAPK4 and MAPK13) and protein kinase D1 (PKD1) in controlling insulin secretion and β cell survival.
The role of the p38 MAPK pathway in diabetes is not well defined, although p38 MAPK phosphorylation is increased in the skeletal muscle and adipocytes of patients with type 2 diabetes and this signaling pathway has been suggested to contribute to the pathogenesis of insulin resistance (Koistinen et al. 2003 , Carlson et al., 2003 . The mammalian p38 MAPK family comprises four members (p38α, p38β, p38γ, and p38δ) that are encoded by different genes. Of these four kinases, p38α is widely expressed in different tissues and the most intensively studied. Targeted gene-inactivation experiments in mice have revealed an essential role for p38α in formation of the placenta; p38α inactivation in adult mice has also uncovered important functions for this protein kinase in tissues such as liver and lung (Hui et al. 2007; Ventura et al. 2007 Insufficient production of the hormone insulin by pancreatic β cells results in diabetes. In this issue, Sumara et al. (2009) report key roles for the protein kinases p38δ and PKD1 in the regulation of insulin secretion as well as in the survival of pancreatic β cells. p38γ, or p38δ are viable and show no obvious phenotypes (Sabio et al. 2005; Beardmore et al. 2005) , although this could be explained by possible functional redundancies among the four kinases. The p38β kinase is closely related to p38α but is expressed at very low levels with unknown contributions to p38 MAPK signaling. The remaining two p38 MAPK family members have more restricted expression patterns, with p38δ expressed mainly in the pancreas, kidney, testes, and small intestine and p38γ expressed in skeletal muscle, suggesting that they might have more specialized functions (Goedert et al. 1997) .
Given the high level of p38δ expression in the pancreas where insulinproducing β cells reside, Sumara et al. investigated whether this protein kinase plays a role in glucose homeostasis. Strikingly, p38δ-deficient mice have improved glucose tolerance, which correlates with enhanced insulin exocytosis by pancreatic β cells. Insulin secretion is mediated by the exocytosis of secretory vesicles that contain the hormone and derive from the trans-Golgi network (Figure 1) . To determine how p38δ may be affecting insulin exocytosis, the authors used a mass spectrometrybased proteomic approach and identified PKD1 as a protein that associates with a constitutively active mutant form of p38δ in cultured human cells. PKD1 is known to positively regulate secretion in neuroendocrine cells and promotes the fission of vesicles destined for exocytosis at the plasma membrane from the trans-Golgi network (Bard and Malhotra, 2006) . Consistent with PKD1 being the target of p38δ during regulation of insulin exocytosis, p38δ appears to regulate trans-Golgi network fission events in cultured murine β cells. In addition, pharmacological inhibition of PKD1 activation restores insulin secretion by β cells as well as glucose tolerance in p38δ-deficient mice.
The authors find that p38δ phosphorylates PKD1 on two residues (Ser397 and Ser401 in human PKD1) in vitro. Mutation analysis further suggests that these phosphorylation events reduce PKD1 activity. Consistent with this, higher levels of active PKD1 are detected in the pancreas of p38δ-deficient mice compared with wild-type mice. Moreover, short hairpin RNA-mediated downregulation of p38δ expression in cultured mouse β cells also increases PKD1 activity. Taken together, the results suggest that p38δ negatively regulates insulin secretion by decreasing PKD1 activity and thus inhibiting PKD1-directed fission of insulin-containing vesicles from the trans-Golgi network destined for exocytosis. How phosphorylation of PKD1 by p38δ limits PKD1 activity still remains unclear. Phosphorylation by p38δ could directly modulate PKD1 kinase activity or alter its subcellular localization. Alternatively, phosphorylation by p38δ could prevent the association of PKD1 with diacylglycerol (which recruits the kinase to the trans-Golgi network) or could preclude PKD1 activation by protein kinase Cη.
Regardless of the precise mechanism of PKD1 regulation by p38δ, the work of Sumara and colleagues strongly suggests that the p38δ-PKD1 module is a key regulator of insulin exocytosis in pancreatic β cells.
Interestingly, p38δ seems to be an important regulator of other processes related to the pathogenesis of diabetes, namely insulin resistance and β cell death. Sumara et al. observe that p38δ-deficient mice on a high-fat diet develop less severe peripheral insulin resistance than do wild-type mice fed the same diet. Furthermore, the pancreatic β cells of the p38δ-deficient mice are less sensitive to oxidative stress caused by the drug streptozotocin. Increased PKD1 activity in the absence of p38δ-imposed inhibition appears to be directly mediating this protective effect, as treatment of the p38δ-deficient mice with a drug that impairs PKD1 activation results in the renewal of β cell susceptibility to oxidative stress. How PKD1 activity may protect pancreatic β cells against apoptosis induced by oxidative stress is unknown, although it has been proposed that PKD1 mediates the activation of the prosurvival transcription factor NF-κB, which is induced by oxidative stress (Storz and Toker, 2003) . Thus, the regulation of PKD1 appears to be a critical function of p38δ activity in vivo both in the context of increased insulin secretion induced by high glucose and in β cell survival.
Beyond advancing our understanding of the physiological role of the p38δ MAPK, the work of Sumara et al. suggests that the signaling module of p38δ and PKD1 may be a potential therapeutic target for human diabetes. Future studies will need to elucidate how p38δ activity is regulated during normal pancreatic β cell function and the molecular mechanisms underlying PKD1 regulation of vesicle trafficking and β cell survival. Whether the regulation of PKD1 activity by p38δ could be a general mechanism for controlling macromolecule secretion as well as protein transport from the trans-Golgi network to the cell surface in nonsecretory cells remain exciting questions for further exploration.
